ArticleDigestive diseases and sciences2026
Dihydroartemisinin: A Targeting Agent of CCT3-Mediated Oxidative Stress to Enhance the Antitumor Activity of Doxorubicin in Hepatocellular Carcinoma.
Article in Digestive diseases and sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundLiver cancer is the third most common cause of cancer-related death after lung and colorectal cancers. Hepatocellular carcinoma (LIHC) is the predominant subtype. Doxorubicin (DOX), an anthracycline chemotherapy drug, is extensively employed in the clinical treatment of early-stage and mid-stage liver cancer. Unfortunately, resistance that develops with long-term treatment severely undermines its therapeutic efficacy. Dihydroartemisinin (DHA), an antimalarial drug, has shown great potential in modulating the tumor microenvironment and inhibiting tumor growth, yet our understanding of its mechanisms remains limited.
methodsNetwork pharmacology identified CCT3 as a potential DHA target. Autodock predicted the binding of CCT3 and DHA. CCT3 expression in tumor and normal samples was analyzed using the TCGA-LIHC dataset. GSEA mapped out the pathways enriched by CCT3. qPCR and WB were used to measure CCT3 expression. Drug affinity responsive target stability assay verified the binding of CCT3 and DHA. The effects of DOX and DHA on cancer cell viability were probed using CCK-8, TUNEL, and flow cytometry. Cellular oxidative stress (OS) levels were assessed with intracellular reactive oxygen species (ROS) detection and JC-1 staining.
resultsDHA and DOX both proved effective in suppressing cancer cell viability and boosting apoptosis. Their combined use further amplified these effects. CCT3 was identified as a crucial target protein for DHA in LIHC treatment, with a strong binding capacity. This protein was particularly enriched in pathways associated with OS. In DOX-resistant cells, overexpressing CCT3 remarkably heightened resistance and reduced apoptosis, which possibly stemmed from the role of CCT3 in maintaining cellular ROS and mitochondrial membrane potential homeostasis, thereby reducing OS. Notably, these effects of CCT3 could be effectively inhibited by targeting DHA.
conclusionDHA can target and inhibit CCT3 to induce OS, thereby enhancing the therapeutic efficacy of DOX.
Indexed as
Identifiers
41205108What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.